Environmental factors in Parkinson's disease

NeuroToxicology

Volumn 23, Issue 4-5, 2002, Pages 487-502

  Di Monte, Donato A ^a   Lavasani, Mitra ^a   Manning Bog, Amy B ^a  

^a PARKINSON S INSTITUTE   (United States)

Author keywords

MPTP; Neurodegeneration; Neurotoxicant; Pesticides; Smoking

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROPROTECTIVE AGENT; NEUROTOXIN; ALPHA SYNUCLEIN; DIETHYLDITHIOCARBAMIC ACID; DOPAMINE TRANSPORTER; PESTICIDE;

ANIMAL; CHEMICALLY INDUCED DISORDER; ENVIRONMENT; HUMAN; NERVE DEGENERATION; PARKINSON DISEASE; PATHOLOGY; REVIEW; RISK FACTOR; AGING; CLINICAL FEATURE; CONFERENCE PAPER; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; GENETIC PREDISPOSITION; INCIDENCE; INFLAMMATION; NEUROPATHOLOGY; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSONISM; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; TOBACCO;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DOPAMINE AGENTS; ENVIRONMENT; HUMANS; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; RISK FACTORS;

NICOTIANA TABACUM;

EID: 0036777177     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(02)00099-2     Document Type: Article

References (161)

1. Albores R, Neafsey EJ, Drucker G, Fields JZ, Collins MA. Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine. Proc Natl Acad Sci USA 1990;87:9368-72.
2. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949-56.
3. Baumann RJ, Jameson HD, McKean HE, Haack DG, Weisberg LM. Cigarette smoking and Parkinson disease: 1. Comparison with matched neighbors. Neurology 1980;30:839-43.
4. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-55.
5. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-6.
6. Bhatt MH, Elias MA, Mankodi AK. Acute and reversible parkinsonism due to organophosphate pesticide intoxication: five cases. Neurology 1999;52:1467-71.
7. Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 1999;823:1-10.
8. Chan P, Langston JW, Irwin I, DeLanney LE, Di Monte DA. 2- Deoxyglucose enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine-induced ATP loss in the mouse brain. J Neurochem 1993;61:610-6.
9. Chan P, Di Monte DA, Langston JW, Janson AM. (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice. J Pharmacol Exp Ther 1997;280:439-46.
10. +, a metabolite of MPTP, by brain synaptosomes. Biochem Biophys Res Commun 1985;128:1228-32.
11. Cleeter MW, Cooper JM, Schapira AH. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridium: evidence for free radical involvement. J Neurochem 1992;58:786-9.
12. Cleeter MW, Cooper JM, Darley-Usmar VM, Moncada S, Schapira AH. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain. FEBS Lett 1994;345:50-4.
13. Collins MA, Origitano TC. Catecholamine-derived tetrahydroisoquinolines: O-methylation patterns and regional brain distribution following intraventricular administration in rats. J Neurochem 1983;41:1569-75.
14. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998;4:1318-20.
15. Corrigan FM, Murray L, Wyatt CL, Shore RF. Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson's disease. Exp Neurol 1998;150:339-42.
16. Corsini GU, Pintus S, Chiueh CC, Weiss JF, Kopin IJ. 1-Methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate. Eur J Pharmacol 1985;119:127-8.
17. + and ATP induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor benzamide. Brain Res 1998;809:58-67.
18. Court JA, Lloyd S, Thomas N, Piggot MA, Marshall EF, Morris CM, et al. Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience 1998;87:63-78.
19. Daniels AJ, Reinhard Jr, JF. Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffin granules via the catecholamine transporter. J Biol Chem 1988;263:5034-6.
20. Davis KL, Yesavage JA, Berger PA. Single case study. Possible organophosphate-induced parkinsonism. J Nerv Ment Dis 1978;166:222-5.
21. Denton T, Howard BD. A dopaminergic cell line variant resistant to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 1987;49:622-30.
22. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-6.
23. Dexter DT, Carayon A, Vidailhet M, Ruberg M, Agid F, Agid Y, et al. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 1990;55:16-20.
24. Di Monte D, Langston JW. MPTP-induced parkinsonism in non-human primates. In: Schneider JS, Gupta M, editors. Current concepts in Parkinson's disease research. Kirkland (WA): Hogrefe & Huber Publishers; 1993. p. 159-79.
25. Di Monte D, Jewell SA, Ekstrom G, Sandy MS, Smith MT. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in hepatocytes. Biochem Biophys Res Commun 1986;137:310-5.
26. Di Monte DA, Chan P, Sandy MS. Glutathione in Parkinson's disease: a link between oxidative stress and mitochondrial damage? Ann Neurol 1992;32(Suppl):S111-5.
27. Di Monte DA, Royland JE, Anderson A, Castagnoli K, Castagnoli Jr, N, Langston JW. Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity. J Neurochem 1997;69:1771-3.
28. Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston JW. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord 2000;15:459-66.
29. Drucker G, Raikoff K, Neafsey EJ, Collins MA. Dopamine uptake inhibitory capacities of beta-carboline and 3,4-dihydro-beta- carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products. Brain Res 1990;509:125-33.
30. Earle KM. Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. J Neuropathol Exp Neurol 1968;27:1-14.
31. Endo A, Hara S, Kano S, Kuriiwa F. Effects of a paraquat containing herbicide, Gramoxon, on the central monoamines and acetylcholine in mice. Res Commun Psychol Psychiatr Behav 1988;13:261-70.
32. Engel LS, Checkoway H, Keifer MC, Seixas NS, Longstreth Jr, WT, Scott KC, et al. Parkinsonism and occupational exposure to pesticides. Occup Environ Med 2001;58:582-9.
33. Fall PA, Fredrikson M, Axelson O, Granerus AK. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov Disord 1999;14:28-37.
34. Ferrante RJ, Schulz JB, Kowall NW, Beal MF. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 1997;753:157-62.
35. Ferraz HB, Bertolucci PH, Pereira JS, Lima JG, Andrade LA. Chronic exposure to the fungicide maneb may produce symptoms and signs of CNS manganese intoxication. Neurology 1988;38:550-3.
36. Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR. Parkinson's disease and brain levels of organochlorine pesticides. Ann Neurol 1994;36:100-3.
37. Fomo LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 1986;20:449-55.
38. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996a;379:733-6.
39. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 1996b;93:14065-9.
40. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 1997;69:1322-5.
41. Gearhart DA, Collins MA, Lee JM, Neafsey EJ. Increased beta-carboline 9N-methyltransferase activity in the frontal cortex of Parkinson's disease. Neurobiol Dis 2000;7:201-11.
42. Golbe LI, Farrell TM, Davis PH. Follow-up study of early-life protective and risk factors in Parkinson's disease. Mov Disord 1990;5:66-70.
43. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, et al. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 1997;48:650-8.
44. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson's disease with exposure to pesticides, farming well water, and rural living. Neurology 1998;50:1346-50.
45. Gorell JM, Rybicki BA, Johnson CC, Peterson EL. Smoking and Parkinson's disease: a dose-response relationship. Neurology 1999;52:115-9.
46. Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 1994;139:1129-38.
47. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinines. Mol Pharmacol 1978;14:633-43.
48. Hadjiconstantinou M, Hubble JP, Wemlinger TA, Neff NH. Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists. J Pharmacol Exp Ther 1994;270:639-44.
49. Heikkila RE, Sonsalla PK. The use of the MPTP-treated mouse as an animal model of parkinsonism. Can J Neurol Sci 1987;14:436-40.
50. Heikkila RE, Nicklas WJ, Vyas I, Duvoisin RC. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridium ion after their stereotaxic administration to rats: implications for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Neurosci Lett 1985;62:389-94.
51. Heikkila RE, Cabbat FS, Cohen G. In vivo inhibition of superoxide dismutase in mice by diethyldithiocarbamate. J Biol Chem 1976;251:2182-5.
52. Hellenbrand W, Seidler A, Robra BP, Vieregge P, Oertel WH, Joerg J, et al. Smoking and Parkinson's disease: a case-control study in Germany. Int J Epidemiol 1997;26:328-39.
53. Hertzman C, Wiens M, Bowering D, Snow B, Calne D. Parkinson's disease: a case-control study of occupational and environmental risk factors. Am J Ind Med 1990;17:349-55.
54. Ho SC, Woo J, Lee CM. Epidemiological study of Parkinson's disease in Hong Kong. Neurology 1989;39:1314-8.
55. Hoogenraad TU. Dithiocarbamates and Parkinson's disease. Lancet 1988;1:767.
56. Hubble JP, Kurth JH, Glatt SL, Kurth MC, Schellenberg GD, Hassanein RE, et al. Gene-toxin interaction as a putative risk factor for Parkinson's disease with dementia. Neuroepidemiology 1998;17:96-104.
57. Irwin I, Wu EY, DeLanney LE, Trevor A, Langston JW. The effect of diethyldithiocarbamate on the biodisposition of MPTP: an explanation for enhanced neurotoxicity. Eur J Pharmacol 1987;141:209-17.
58. Irwin I, Di Monte DA, Thiruchelvam M, Verma M, Karich A, Putagnari G, et al. Diethyldithiocarbamate (DDC): a promoter of dopaminergic toxicity. The Toxicologist 1996;30:263-4.
59. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995;4:257-69.
60. Janson AM, Moller A. Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesodiencephalic hemitransection: an analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. Neuroscience 1993;57:931-41.
61. Janson AM, Fuxe K, Goldstein M. Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse. Clin Invest 1992;70:232-8.
62. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 1985;82:2173-7.
63. Kawai H, Makino Y, Hirobe M, Ohta S. Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivatives: uptake by dopamine transporter and activity to induce parkinsonism. J Neurochem 1998;70:745-51.
64. Khalil AA, Steyn S, Castagnoli Jr, N. Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves. Chem Res Toxicol 2000;13:31-5.
65. Klivenyi P, Andreassen OA, Ferrante RJ, Dedeoglu A, Mueller G, Lancelot E, et al. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci 2000;20:1-7.
66. Koller WC. Paraquat and Parkinson's disease. Neurology 1986;36:1147.
67. Koller W, Vetere-Overfield B, Gray C, Alexander C, Chin T, Dolezal J, et al. Environmental risk factors in Parkinson's disease. Neurology 1990;40:1218-21.
68. Koller WC, Langston JW, Hubble JP, Irwin I, Zack M, Golbe L, et al. Does a long preclinical period occur in Parkinson's disease? Neurology 1991;41(5 (Suppl 2)):8-13.
69. Kotake Y, Tasaki Y, Makino Y, Ohta S, Hirobe M. 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF. J Neurochem 1995;65:2633-8.
70. Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. NeuroReport 2000;11:211-3.
71. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106-8.
72. Langston JW, Koller WC. The next frontier in Parkinson's disease: presymptomatic detection. Neurology 1991;41(5 (Suppl 2)):5-7.
73. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-80.
74. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999;46:598-605.
75. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999;12:1403-9.
76. Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, et al. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 1997;48:1583-8.
77. Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HS, Sucher NJ, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993;364:626-32.
78. Mackenzie GM, Jackson MJ, Jenner P, Marsden CD. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset. Synapse 1997;26:301-16.
79. Makino Y, Ohta S, Tachikawa O, Hirobe M. Presence of tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline in foods: compounds related to Parkinson's disease. Life Sci 1988;43:373-8.
80. Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice. J Biol Chem 2002;277:1641-4.
81. Marder K, Tang MX, Mejia H, Alfaro B, Cote L, Louis E, et al. Risk of Parkinson's disease among first-degree relatives: A community-based study. Neurology 1996;47:155-60.
82. Marder K, Logroscino G, Alfaro B, Mejia H, Halim A, Louis E, et al. Environmental risk factors for Parkinson's disease in an urban multiethnic community. Neurology 1998;50:279-81.
83. Marey-Semper I, Gelman M, Levi-Strauss M. The high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopaminergic neurons from the substantia nigra. Eur J Neurosci 1993;5:1029-34.
84. Marey-Semper I, Gelman M, Levi-Strauss M. A selective toxicity toward cultured mesencephalic dopaminergic neurons is induced by the synergistic effects of energetic metabolism impairment and NMDA receptor activation. J Neurosci 1995;15:5912-8.
85. Marin P, Maus M, Desagher S, Glowinski J, Premont J. Nicotine protects cultured striatal neurones against N-methyl-D-aspartate receptor-mediated neurotoxicity. NeuroReport 1994;5:1977-80.
86. Marini AM, Schwartz JP, Kopin IJ. The neurotoxicity of 1-methyl- 4-phenylpyridinium in cultured cerebellar granule cells. J Neurosci 1989;9:3665-72.
87. Maruyama W, Nakahara D, Ota M, Takahashi T, Takahashi A, Nagatsu T, et al. N-methylation of dopamine-derived 6,7-dihdroxy-1,2,3,4-tetrahydroisoquinoline, (R)-salsolinol, in rat brains: in vivo microdialysis study. J Neurochem 1992;59:395-400.
88. Matsubara K, Neafsey EJ, Collins MA. Novel S-adenosyl- methionine-dependent indole-N-methylation of beta-carbolines in brain particulate fractions. J Neurochem 1992;59:511-8.
89. Matsubara K, Collins MA, Akane A, Ikebuchi J, Neafsey EJ, Kagawa M, et al. Potential bioactivated neurotoxicants, N-methylated beta-carbolinium ions, are present in human brain. Brain Res 1993;610:90-6.
90. Matsubara K, Kobayashi S, Kobayashi Y, Yamashita K, Koide H, Hatta M, et al. beta-Carbolinium cations endogenous MPP+ analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurology 1995;45:2240-5.
91. Matsubara K, Gonda T, Sawada H, Uezono T, Kobayashi T, Ohtaki K, et al. Endogenously occurring beta-carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson's disease. J Neurochem 1998;70:727-35.
92. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 2002;10:119-27.
93. McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol 1977;34:33-5.
94. Meco G, Bonifati V, Vanacore N, Fabrizio E. Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate). Scand J Work Environ Health 1994;20:301-5.
95. Michel PP, Dandapani BK, Knusel B, Sanchez-Ramos J, Hefti F. Toxicity of 1-methyl-4-phenypyridinium for rat dopaminergic neurons in culture: selectivity and irreversibility. J Neurochem 1990;54:1102-9.
96. Miller GW, Gainetdinov RR, Levey AI, Caron MG. Dopamine transporters and neuronal injury. Trends Pharmacol Sci 1999a;20:424-9.
97. Miller GW, Kirby ML, Levey AI, Bloomquist JR. Heptachlor alters expression and function of dopamine transporters. Neurotoxicology 1999b;20:631-7.
98. Minana MD, Montoliu C, Llansola M, Grisolia S, Felipo V. Nicotine prevents glutamate-induced proteolysis of the microtubule-associated protein MAP-2 and glutamate neurotoxicity in primary cultures of cerebellar neurons. Neuropharmacology 1998;37:847-57.
99. Morano A, Jimenez-Jimenez FJ, Molina JA, Antolin MA. Risk-factors for Parkinson's disease: a case-control study in the province of Caceres, Spain. Acta Neurol Scand 1994;89:164-70.
100. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F] dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-9.
101. Mukherjee SK, Klaidman LK, Yasharel R, Adams Jr, JD. Increased brain NAD prevents neuronal apoptosis in vivo. Eur J Pharmacol 1997;330:27-34.
102. Muller-Vahl KR, Kolbe H, Dengler R. Transient severe parkinsonism after acute organophosphate poisoning. J Neurol Neurosurg Psychiatry 1999;66:253-4.
103. Mytilineou C, Cohen G. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J Neurochem 1985;45:1951-3.
104. Nagatsu T, Yoshida M. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci Lett 1988;87:178-82.
105. + cause nigrostriatal toxicity after substantia nigra injections in rats. Brain Res 1995;675:279-88.
106. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Life Sci 1985;36:2503-8.
107. Niwa T, Takeda N, Kaneda N, Hashizume Y, Nagatsu T. Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains. Biochem Biophys Res Commun 1987;144:1084-9.
108. Pal PK, Samii A, Calne DB. Manganese neurotoxicity: a review of clinical features. Neurotoxicology 1999;20:227-38.
109. Perry TL, Yong VW, Wall RA, Jones K. Paraquat and two endogenous analogues of the neurotoxic substance N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine do not damage dopaminergic nigrostriatal neurons in the mouse. Neurosci Lett 1986;69:285-9.
110. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
111. Przedborski S, Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Disord 1998;13:35-8.
112. Przedborski S, Kostic V, Jackson-Lewis V, Naini AB, Simonetti S, Fahn S, et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 1992;12:1658-67.
113. Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM. Role of neuronal nitric oxide in 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 1996;93:4565-71.
114. Radi R, Rodriguez M, Castro L, Telleri R. Inhibition of mitochondrial electron transport by peroxynitrite. Arch Biochem Biophys 1994;308:89-95.
115. Rajput AH, Uitti RJ, Stern W, Laverty W. Early onset Parkinson's disease in Saskatchewan-environmental considerations for etiology. Can J Neurol Sci 1986;13:312-6.
116. Ramsay RR, Singer TP. Energy-dependent uptake of N-methyl-4-phenylpyridinium the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem 1986;261:7585-7.
117. Reinhard Jr, JF, Diliberto Jr, EJ, Viveros OH, Daniels AJ. Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc Natl Acad Sci USA 1987;84:8160-4.
118. Ricaurte GA, Langston JW, DeLanney LE, Irwin I, Brooks JD. Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. Neurosci Lett 1985;59:259-64.
119. Ross GW, Abbott RD, Petrovich H, Morens DM, Grandinetti A, Tung KH, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000;283:2674-9.
120. Sanchez-Ramos JR, Hefti F, Weiner WJ. Paraquat and Parkinson's disease. Neurology 1987;37:728.
121. Sanchez-Ramos J, Facca A, Basit A, Song S. Toxicity of dieldrin for dopaminergic neurons in mesencephalic cultures. Exp Neurol 1998;150:263-71.
122. Sanghera MK, Manaye K, McMahon A, Sonsalla PK, German DC. Dopamine transporter mRNA levels are high in midbrain neurons vulnerable to MPTP. NeuroReport 1997;8:3327-31.
123. Sayre LM, Wang FJ, Arora PK, Riachi NJ, Harik SI, Hoppel CL. Dopaminergic neurotoxicity in vivo and inhibition of mitochondrial respiration in vitro by possible endogenous pyridinium-like substances. J Neurochem 1991;57:2106-15.
124. Schapira AH. Evidence for mitochondrial dysfunction in Parkinson's disease-a critical appraisal. Mov Disord 1994;9:125-38.
125. Schultz W, Scarnati E, Sundstrom E, Tsutsumi T, Jonsson G. The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys. Exp Brain Res 1986;63:216-20.
126. Schulz JB, Matthews RT, Muqit MM, Browne SE, Beal MF. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 1995;64:936-9.
127. Sechi GP, Agneti V, Piredda M, Canu M, Deserra F, Omar HA, et al. Acute and persistent parkinsonism after use of diquat. Neurology 1992;42:261-3.
128. Seidler A, Hellenbrand W, Robra BP, Viergge P, Nischan P, Jooerg J, et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 1996;46:1275-84.
129. Semchuck KM, Love EJ, Lee RG. Parkinson's disease and exposure to rural environmental factors: a population based case-control study. Can J Neurol Sci 1991;18:279-86.
130. Semchuck KM, Love EJ, Lee RG. Parkinson's disease and exposure to agricultural work pesticide chemicals. Neurology 1992;42:1328-55.
131. Semchuck KM, Love EJ, Lee RG. Parkinson's disease: A test of the multifactorial etiologic hypothesis. Neurology 1993;43:1173-80.
132. Shimizu K, Ohtaki K, Matsubara K, Aoyama K, Uezono T, Saito O, et al. Carrier-mediated processes in blood-brain barrier penetration and neural uptake of paraquat. Brain Res 2001;906:135-42.
133. Snyder SH, D'Amato RJ. Predicting Parkinson's disease. Nature 1985;317:198-9.
134. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, et al. Increased iron(III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988;74:199-205.
135. Sonsalla PK, Nicklas WJ, Heikkila RE. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 1989;243:398-400.
136. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998;95:6469-73.
137. Spooren WP, Gentsch C, Wiessner C. TUNEL-positive cells in the substantia nigra of C57BL/6 mice after a single bolus of 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 1998;85:649-51.
138. Stern M, Dulaney E, Gruber SB, Golbe L, Bergen M, Hurtig H, et al. The epidemiology of Parkinson's disease. A case-control study of young-onset and old-onset patients. Arch Neurol 1991;48:903-7.
139. Suzuki K, Mizuno Y, Yoshida M. Inhibition of mitochondrial respiration by 1,2,3,4-tetrahydroisoquinoline-like endogenous alkaloids in mouse brain. Neurochem Res 1990;15:705-10.
140. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 1997;94:9938-43.
141. Tanner CM, Chen B, Wang W, Peng M, Liu Z, Liang X, et al. Environmental factors and Parkinson's disease: a case-control study in China. Neurology 1989;39:660-4.
142. Tanner CM, Grabler P, Goetz CG. Occupation and the risk of Parkinson's disease (PD): a case-control study in young-onset patients. Neurology 1990;40(Suppl 1):422.
143. Tanner CM, Hubble J, Chan P. Epidemiology and genetics of Parkinson's disease. In: Watts RL, Koller WL, editors. Movement disorders: neurological principles and practice. New York: McGraw-Hill; 1997. p. 137-52
144. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, et al. Parkinson disease in twins: an etiologic study. JAMA 1999;281:341-6.
145. Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labeling and acridine orange staining. Neuroscience 1997;77:1037-48.
146. Thiffault C, Langston JW, Di Monte DA. Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res 2000;885:283-8.
147. Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory-Slechta DA. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J Neurosci 2000;20:9207-14.
148. Trojanowski JQ, Lee VM. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 1998;55:151-2.
149. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991;349:414-8.
150. Uversky VN, Li J, Fink AL. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett 2001;500:105-8.
151. Vaccari A, Saba P. The tyramine-labelled vesicular transporter for dopamine: a putative target of pesticides and neurotoxins. Eur J Pharmacol 1995;292:309-14.
152. Vaglini F, Fascetti F, Fornai F, Maggio R, Corsini GU. (+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice. Brain Res 1994;668:194-203.
153. Walters TL, Irwin I, Delfani K, Langston JW, Janson AM. Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP. Exp Neurol 1999;156:62-70.
154. Watanabe H, Uramoto H. Caffeine mimics dopamine receptor agonists without stimulation of dopamine receptors. Neuropharmacology 1986;25:577-81.
155. Widdowson PS, Farnworth MJ, Upton R, Simpson MG. No changes in behaviour, nigro-striatal system neurochemistry or neuronal cell death following toxic multiple oral paraquat administration to rats. Hum Exp Toxicol 1996;15:583-91.
156. Wong GF, Gray CS, Hassanein RS, Koller WC. Environmental risk factors in siblings with Parkinson's disease. Arch Neurol 1991;48:287-9.
157. Wu EY, Langston JW, Di Monte DA. Toxicity of the 1-methyl-4- phenyl-2,3-dihydropyridinium and 1-methyl-4-phenylpyridinium species in primary cultures of mouse astrocytes. J Pharmacol Exp Ther 1992;262:225-30.
158. Youngster SK, Nicklas WJ, Heikkila RE. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. II. Evaluation of the biological activity of the pyridinium metabolites formed from the monoamine oxidase-catalyzed oxidation of MPTP analogs. J Pharmacol Exp Ther 1989a;249:829-35.
159. Youngster SK, Sonsalla PK, Sieber BA, Heikkila RE. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs. J Pharmacol Exp Ther 1989b;249:820-8.
160. Zecca L, Pietra R, Goj C, Mecacci C, Radice D, Sabbioni E. Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J Neurochem 1994;62:1097-101.
161. Zuddas A, Oberto G, Vaglini F, Fascetti F, Fornai F, Coisini GU. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates. J Neurochem 1992;59:733-9.